Clinical Study

Real World Study Of Safety And Tolerability Of Switching From Different Ms Drugs To Newly Approved Mayzent (Siponimod)

Posted Date: Jun 16, 2019

  • Investigator: Aram Zabeti
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to assess early phase safety and tolerability of converting patients from approved oral and injectable RMS DMTs to siponimod. The results of this study will guide clinically relevant decisions related to the transition from frequently used RMS DMTs to siponimod and provide clinically relevant data on safety and tolerability for healthcare providers who are considering converting patients from currently approved RMS DMT to siponimod.


Male Or Female Aged 18 To 65 Years Patients With Rms With Or Without Progressive Features And Disability Status At Screening With An Edss Score Of >2.0 To 6.5 Who Having Been Continuously Treated With Beta-Interferons, Glatiramer Acetate, Fingolimod, Dimethyl Fumarate, Or Teriflunomide For At Least 3 Months At The Time Of Consent.


Mayzent, Safety, Switch Therapy

For More Information:

Molly Winters

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.